At the present time, bone mineral density testing is most commonly estimated using dual energy x-ray absorptiometry. However, limited instrument availability, decreasing reimbursement, and other factors all act to limit testing for many patients. This results in a majority of people at risk and in need of treatment not being identified.

Imaging Therapeutics' technology permits BMD testing to be performed using any conventional x-ray system. Because there are far more conventional systems than dual energy x-ray absorptiometers. OsDx software will help make BMD testing more convenient and readily available. Increased early detection will allow for early drug intervention and lifestyle modifications reducing fractures and their associated morbidity and mortality.

Dr. Patrick Hess, Imaging Therapeutics' President and CEO comments "I am very pleased with achieving this important milestone. It represents the first of several important products that will collectively act to increase capacity for screening osteoporosis as well as significantly improve the ability to assess an individual's risk for osteoporosis-related bone fracture. It is our vision to reduce the enormous societal burden that osteoporosis has become by helping to reduce individual pain, suffering, and cost."

About Imaging Therapeutics, Inc.

Imaging Therapeutics, Inc. is a privately held advanced medical technology company that develops novel, proprietary image processing technology for advancing the treatment and management of osteoporosis and osteoarthritis. A pipeline of software products is being developed to advance the ability of clinicians to screen for, diagnose, monitor, and predict disease.

SOURCE: Imaging Therapeutics, Inc.

Imaging Therapeutics, Inc. 
Patrick Hess, PhD, MBA, FACB, 949-466-9525 
President and CEO 
patrick.hess@imatx.com

Yury Khudyakov, Ph.D., Chief, Molecular Epidemiology and Bioinformatics Laboratory, Division of Viral Hepatitis, Centers for Disease Control and Prevention

"Novel Molecular Technologies for Public Health"

Betty Dragon, Ph.D., Sequenom Senior Vice President, Research & Development

"Noninvasive Prenatal Detection of Genetic Abnormalities Using SEQureDx(TM) Technology"

Daniel H. Farkas, Ph.D., HCLD, FACB, Executive Director, Center for Molecular Medicine

"Real-world Genetic Testing: Translating Science into Routine Clinical Tests"

Jacob A. Canick, Ph.D., Professor of Pathology and Laboratory Medicine, Alpert Medical School at Brown University

"Design And Implementation of a Landmark, Multicenter, Prospective Clinical Study To Validate The Safe And Accurate Detection of Down Syndrome Using SEQureDx(TM) Technology"

Allan T. Bombard, M.D., FACOG, FACS, FACMG, reproductive geneticist, Chief Medical Officer, Sharp Mary Birch Hospital, and Chairman, Clinical Advisory Board

"Are We Facing a Revolution in Noninvasive Prenatal Genetic Diagnostics?"

How: Live over the Internet -- Simply log on to the Web at the address above.

    Contact:  Lippert/Heilshorn & Associates
               Amy Higgins (ahiggins@lhai.com)
               310-691-7100

About Sequenom

Sequenom is committed to providing the best genetic-analysis products for research and the molecular-diagnostic markets. The Company makes available superior solutions for genomic science in biomedical research, livestock and agricultural applications and molecular medicine, as well as for various diagnostic markets, including noninvasive prenatal testing, oncology and infectious diseases. Sequenom's proprietary MassARRAY(R) system delivers reliable and specific data from complex biological samples and from genetic target materials available only in trace amounts.

Minimum Requirements to listen to broadcast:

The Windows Media Player software, downloadable free from http://www.microsoft.com and at least a 56Kbps connection to the Internet. If you experience problems listening to the webcast, send an e-mail to: webcast@multivu.com.

SOURCE Sequenom

http://www.sequenom.com/

- EON Bank Bhd, Malaysia's seventh largest lender by assets, aims to grow loans and deposits by an average of 20 per cent a year over the next three years, helped by aggressive and innovative marketing campaigns.

- Takaful Ikhlas Sdn Bhd, a subsidiary of main board-listed MNRB Holdings Bhd, is mulling plans to sell its offshore takaful products overseas, its top executive said.

- FACB Industries Inc Bhd said it is exiting the property sector after 11 years to focus on its steel operations.

- Dutch electronics group Philips said it does not expect any slowdown in the economy to impact the growth of its healthcare segment in Malaysia.

- Information communications technology (ICT) company the Skali Group is on track to deliver a total of 152 upgraded websites to its clients by year-end.

THE STAR:

- Hai-O Enterprise Bhd's fast-expanding earnings, a potential dividend yield of about 12% and a cash-rich war chest are set to give investors at least some assurance amid the weakening purchasing power of consumers due to rising inflation and slowing economic growth, analysts said.

- The Melewar group's conditional voluntary takeover offer for oil and gas company M3nergy Bhd at RM1.20 per share has been opposed by several minority shareholders who described the offer price as too low for a profitable and viable company.

- Nova MSC Bhd is confident of returning to the black in its financial year ending March 31 (FY09) on a fast expanding order book amid a promising outlook, especially in overseas sales, says chief executive officer Steven Chan Wing Kong.

- Global markets entered into a flux when the US governments initial US$700bil bailout proposal last week did not materialise.

- Analysts say Malayan Banking Bhds (Maybank) revised acquisition price of PT Bank Internasional Indonesia Tbk (BII) is still expensive despite a rebate of RM758.9mil.

According to Dr. Wittliff, "Advantages of the Ziplex automated system to our research include retention of tissue biopsy custody and the rapid, reproducible analyses of gene subsets to investigate breast cancer behavior in order to identify clinically relevant molecular signatures."

Dr. Wittliff was among the first investigators to prove that the expression of estrogen receptors in breast cancer predicted a patient's response to hormone therapy. This finding led to collaborations with the National Surgical Adjuvant Breast Project (NSABP), establishing Tamoxifen as adjuvant therapy for breast cancer and use of receptor proteins as tissue biomarkers of a patient's prognosis and response. With NEN/Dupont, Dr. Wittliff developed the original FDA-approved kits for assessing receptors in biopsies. His laboratory was designated the National Reference Facility for performing quality assurance (QA) surveys of receptor testing for historical clinical trials in North America and for establishing the College of American Pathologists QA Surveys. In recognition of his contributions to medicine, the University of Innsbruck, Austria, awarded Dr. Wittliff, Doctor of Medicine honoris causa. The American Association for Clinical Chemistry honored him with an award for Outstanding Contributions to Clinical Chemistry in a Selected Area of Research; he is also the recipient of the Distinguished Scientist's Award by the Clinical Ligand Assay Society. In 2004, the American Cancer Society recognized his lifetime achievements with the Goldsmith Research Excellence Award. His research team is now working with Xceed to develop clinically related tests for breast and other cancers using its proprietary Ziplex System. Dr. Wittliff's discoveries and development of a unique tumor marker database resulted in the filing of new patents for the University of Louisville and the licensing of his technologies.

About Xceed Molecular (www.XceedMolecular.com)

Xceed's vision is to advance molecular diagnostics by successfully translating novel multiplex tests into routine clinical practice and to create robust diagnostic solutions to improve disease outcomes. Our products comprise the award-winning Ziplex System for automated gene-expression analysis (available in the US and Canada for research use only), gene-expression services, and pre-configured arrays - Xpress Chips. Xceed is also developing multiplexed genomic tests for the Ziplex platform, both internally and with strategic partners. Xceed's R&D and manufacturing are headquartered in Toronto, Ontario, with executive offices in Wellesley, Massachusetts.

SOURCE Xceed Molecular

http://www.xceedmolecular.com